Samsara Biocapital portfolio
Concentrated managerInvestment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Samsara Biocapital reported a $1.2 bn portfolio of 24 positions to the SEC as of the end of Q2 2026. Its largest positions are SRRK, ALMS, MLYS. During the quarter it opened Artiva Biotherapeutics.
Sections with a free account
What changed this quarter
8 positions with a change (1 new, 2 added to, 4 trimmed, 1 sold); also, 3 entered through an IPO, 1 exited through an acquisition or merger. 1 is listed here: those of 0.5 points of the portfolio or more (up to 12).
- Newly listedAlamar BiosciencesALMR5.5% of the portfolio
- Newly listedParabilis MedicinesPBLS1.3% of the portfolio
It started trading this quarter: it appears in a 13F for the first time. The filing does not say whether the manager already held it before the listing, so it is not counted as a purchase.
- Artiva Biotherapeutics+0.8 ppof portfolioNew— → 0.8%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Scholar Rock HoldingSRRK31.2%
- AlumisALMS14.7%
- Mineralys TherapeuticsMLYS13.0%
- SepternaSEPN8.7%
- Alamar BiosciencesALMR5.5%
- NeurogeneNGNE4.4%
- Kalaris TherapeuticsKLRS4.3%
- SpyGlass PharmaSGP3.9%
- Sutro BiopharmaSTRO2.9%
- InventivaIVA2.0%
- Jade BiosciencesJBIO1.3%
- Parabilis MedicinesPBLS1.3%
- vTv TherapeuticsVTVT0.9%
- Aquestive TherapeuticsAQST0.9%
- NkartaNKTX0.8%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 100%
How its portfolio changed (8 quarters)
Q2 2026: 24
Q2 2026: 90%
Q2 2026: 4.8%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- Mcdonald Capital InvestorsInvestment firm · $1.2 bn
- Ophir Asset Management PtyInvestment firm · $1.2 bn
- RDST CapitalInvestment firm · $1.2 bn
- Tweedy, BrowneInvestment firm · $1.2 bn
- 140 Summer PartnersInvestment firm · $1.2 bn
- Biglari CapitalInvestment firm · $1.2 bn